Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.70 |
| ▸ | MAPT | P10636 | 8/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | MYOC | Q99972 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 4/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111727 | 0.89 | MAPT (0.71) | MEN1KMT2AMAPTMAPK1NPC1 | |
| SCHEMBL4106750 | 0.87 | MEN1 (0.68) | MEN1KMT2AMAPTMAPK1NPC1 | |
| SCHEMBL4117970 | 0.87 | MEN1 (0.62) | MEN1KMT2AMAPTMAPK1NPC1 | |
| SCHEMBL10576308 | 0.86 | MAPT (0.86) | MEN1KMT2AMAPTMAPK1NPC1 | |
| SCHEMBL11348624 | 0.84 | PTGS2 (0.67) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL45896 | 0.84 | PTGS2 (0.80) | MEN1KMT2AMAPTMAPK1NPSR1 | |
| SCHEMBL4128446 | 0.83 | MEN1 (0.77) | MEN1KMT2AMAPTMAPK1NPC1 | |
| SCHEMBL11004478 | 0.83 | MEN1 (1.00) | MEN1KMT2AMAPTMAPK1NPC1 | |
| SCHEMBL6302157 | 0.82 | MEN1 (1.00) | MEN1KMT2AMAPTMAPK1NPC1 | |
| SCHEMBL1177730 | 0.82 | MEN1 (1.00) | MEN1KMT2AMAPTMAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | MEN1 3273/4885KMT2A 2807/4885MAPT 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.